Gattex (teduglutide) / Takeda - LARVOL DELTA

Teduglutide for treatment-refractory severe intestinal acute graft-versus-host disease - a multicenter survey. (PubMed, Bone Marrow Transplant) - "No specific teduglutide-related toxicity was observed. Our retrospective analysis suggests that teduglutide is safe and has activity in a fraction of patients with intestinal SR-aGVHD, which needs validation in a prospective trial."

Journal • Acute Graft versus Host Disease • Graft versus Host Disease • Immunology • Transplantation

Comprehensive analysis of adverse drug reactions associated with Teduglutide: post-marketing insights and safety implications. (PubMed, Expert Opin Drug Saf) - "Teduglutide is associated with significant ADRs necessitating vigilant monitoring while managing SBS patients, particularly for gastrointestinal health and infection risks. FAERS data limitations restrict causality determination, highlighting the need for further research to optimize safety."

Adverse drug reaction • Journal • P4 data • Cardiovascular • Gastrointestinal Disorder • Infectious Disease • Psychiatry • Short Bowel Syndrome

Drug-induced kidney stones: a real-world pharmacovigilance study using the FDA adverse event reporting system database. (PubMed, Front Pharmacol) - "The top 5 drugs most frequently linked to kidney stone cases were adalimumab (2,636 cases), infliximab (1,266 cases), interferon beta-1a (920 cases), sodium oxybate (877 cases), and teriparatide (836 cases). Notably, certain drugs like lansoprazole (ROR 7.2, 95% CI 6.62-7.84), Xywav (ROR 7.1, 95% CI 6.03-8.35), and teduglutide (ROR 5.54, 95% CI 4.83-6.36) showed significant risk signals...Our analysis of FAERS data revealed new risk signals for kidney stones not indicated in the labels of 33 drugs. Close monitoring is recommended when using these medications, and further research is needed to investigate the mechanisms behind drug-induced kidney stone formation."

Adverse events • Journal • Real-world evidence • Nephrology • Renal Calculi

A Study of Teduglutide (Revestive®) in Participants With Short Bowel Syndrome (SBS) in Canada (clinicaltrials.gov) - P=N/A | N=52 | Completed | Sponsor: Takeda | Recruiting ➔ Completed | N=100 ➔ 52

Enrollment change • Trial completion • Gastrointestinal Disorder • Short Bowel Syndrome

Efficacy of Teduglutide in the treatment of acute myocardial infarction: a prospective single-center randomized controlled study (ChiCTR) - P4 | N=232 | Not yet recruiting | Sponsor: The first affiliated hospital of anhui medical university; The first affiliated hospital of anhui medical university

New P4 trial • Cardiovascular • Myocardial Infarction

European Consensus on Malabsorption-UEG & SIGE, LGA, SPG, SRGH, CGS, ESPCG, EAGEN, ESPEN, and ESPGHAN. Part 1: Definitions, Clinical Phenotypes, and Diagnostic Testing for Malabsorption. (PubMed, United European Gastroenterol J) - "In patients with short bowel syndrome, teduglutide proved effective in reducing the need for parenteral nutrition, thus improving the quality of life of these patients. Primary care physicians play a central role in the early detection of malabsorption and should be involved in multidisciplinary teams for improving the overall management of these patients. In this European consensus, involving ten scientific societies and several experts, we have dissected all the issues around malabsorption, including the definitions and diagnostic testing (Part 1), high-risk categories and special populations, nutritional assessment and management, and primary care perspective (Part 2)."

Journal • Review • Celiac Disease • Crohn's disease • Cystic Fibrosis • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Immunology • Inflammatory Bowel Disease • Pancreatitis • Pulmonary Disease • Respiratory Diseases • Short Bowel Syndrome

Incorporating Caregiver Burden in Japans Cost-Effectiveness Evaluation: A Case Study of Teduglutide for Pediatric Short Bowel Syndrome (ISPOR 2025) - "This study aimed to integrate caregiver burden into cost-effectiveness evaluations within Japan's healthcare system, using teduglutide, a recombinant human glucagon-like peptide 2 analogue that reduces PS dependence, as a case study. A Markov model was used to assess the costs and effectiveness of teduglutide compared to standard of care for pediatric SBS patients in Japan, with a particular focus on caregiver utility relative to the usual public healthcare payer perspective. This study illustrates the practical steps for incorporating caregiver burden into Japan's cost-effectiveness analyses, using pediatric SBS as an example. This expanded analysis captures a broader value, potentially guiding more informed resource allocation in Japan's healthcare context."

Case study • Clinical • Cost effectiveness • HEOR • Gastrointestinal Disorder • Pediatrics • Short Bowel Syndrome

GLP-2 prevents antipsychotics-induced metabolic dysfunction in mice. (PubMed, Nat Metab) - "Here we demonstrate that a glucagon-like peptide 2 analogue, teduglutide, effectively prevents olanzapine-induced hypothermia and weight gain, and restores glucose tolerance and insulin sensitivity in mice. More importantly, chemogenetic activation of VMHPdyn neurons abolishes olanzapine-induced hypothermia and excessive weight gain, although the psychotropic effects remain intact. Together, our data show that VMHPdyn neurons are the crucial mediator of antipsychotic-induced metabolic dysfunction and glucagon-like peptide 2 receptor agonism may be an effective target to mitigate both acute and chronic side effects."

Journal • Preclinical • CNS Disorders • Metabolic Disorders

Glucagon-like peptide-2 pharmacotherapy activates hepatic Farnesoid X receptor-signaling to attenuate resection-associated bile acid loss in mice. (PubMed, Mol Metab) - "Acute concentration of the SeHCAT-signal into the hepatobiliary system was observed. Teduglutide induced significant repression of hepatic cyp8b1 expression, which was associated with induction of MAF BZIP Transcription Factor G. The data suggest that GLP-2-pharmacotherapy in mice significantly slows bile acid circulation primarily via hepatic Farnesoid X receptor-signaling."

Journal • Preclinical • Gastrointestinal Disorder • Short Bowel Syndrome • CYP8B1

European Consensus on Malabsorption-UEG & SIGE, LGA, SPG, SRGH, CGS, ESPCG, EAGEN, ESPEN, and ESPGHAN: Part 2: Screening, Special Populations, Nutritional Goals, Supportive Care, Primary Care Perspective. (PubMed, United European Gastroenterol J) - "In patients with short bowel syndrome, teduglutide proved effective in reducing the need for parenteral nutrition, thus improving the quality of life of these patients. Primary care physicians have a central role in early detection of malabsorption and should be involved into multidisciplinary teams for improving the overall management of these patients. In this European consensus, involving 10 scientific societies and several experts, we have dissected all the issues around malabsorption, including the definitions and diagnostic testing (Part 1), high-risk categories and special populations, nutritional assessment and management, and primary care perspective (Part 2)."

Journal • Review • Celiac Disease • Crohn's disease • Cystic Fibrosis • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Immunology • Inflammatory Bowel Disease • Pancreatitis • Pulmonary Disease • Respiratory Diseases • Short Bowel Syndrome

Short bowel syndrome and d-lactic acidosis: A case report with supplemental home parenteral nutrition and teduglutide. (PubMed, Endocrinol Diabetes Nutr (Engl Ed)) - "This report presents a case of a patient on teduglutide for SBS who experienced an episode of d-lactic acidosis. To date, there are no documented cases in the literature of similar episodes in adult patients undergoing therapy with GLP2 analogs."

Journal • Review • Gastrointestinal Disorder • Metabolic Disorders • Short Bowel Syndrome

Survival and parenteral nutrition dependence in patients aged 65 and older with short bowel syndrome: a retrospective observational cohort study. (PubMed, Am J Clin Nutr) - "Nearly half of SBS-CIF patients on PS were aged ≥65, with PS dependence and survival rates comparable to younger patients. These findings suggest that age should not be a barrier to PS initiation."

Journal • Observational data • Retrospective data • Cardiovascular • Crohn's disease • Dyslipidemia • Gastroenterology • Gastrointestinal Disorder • Hypertension • Immunology • Inflammatory Bowel Disease • Metabolic Disorders • Oncology • Pulmonary Arterial Hypertension • Short Bowel Syndrome

LONG-TERM EFFECTIVENESS OF TEDUGLUTIDE IN ADULTS WITH SHORT BOWEL SYNDROME-ASSOCIATED INTESTINAL FAILURE: INTERIM ANALYSIS OF THE US SUBPOPULATION FROM A GLOBAL MULTICENTER REGISTRY STUDY (DDW 2025) - No abstract available

Clinical • Gastrointestinal Disorder • Short Bowel Syndrome

LONG-TERM EFFECTIVENESS OF TEDUGLUTIDE IN ADULTS WITH SHORT BOWEL SYNDROME-ASSOCIATED INTESTINAL FAILURE: INTERIM ANALYSIS FROM A GLOBAL MULTICENTER REGISTRY STUDY (DDW 2025) - No abstract available

Clinical • Gastrointestinal Disorder • Short Bowel Syndrome

LONG-TERM EFFECTIVENESS OF TEDUGLUTIDE FOR PATIENTS WITH CROHN'S DISEASE ON PARENTERAL SUPPORT FOR SHORT BOWEL SYNDROME ASSOCIATED WITH INTESTINAL FAILURE (DDW 2025) - No abstract available

Clinical • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Short Bowel Syndrome

Successful treatment with teduglutide for an adolescent with cerebral palsy accompanied by short bowel syndrome. (PubMed, Pediatr Int) - No abstract available

Journal • Cerebral Palsy • CNS Disorders • Developmental Disorders • Gastrointestinal Disorder • Mental Retardation • Short Bowel Syndrome

Real-world experience of Teduglutide use in adults with short bowel syndrome: A seven-year international multicenter survey. (PubMed, Clin Nutr) - "This is the largest analysis of Teduglutide's real-world setting in SBS-IF. Clinicians preferentially selected for treatment patients with better prognostic indicators. Outcomes were significantly better in centers with higher Teduglutide treatment volumes, emphasizing the need for specialized referral centers to optimize care for SBS-IF patients."

Journal • Real-world evidence • Gastrointestinal Disorder • Short Bowel Syndrome

The role of the proglucagon-derived peptide GLP-2 in resection-triggered growth and barrier response in mice (ECCO-IBD 2025) - "In the second model, male C57BL/6J mice were divided into the following groups: non-operated controls +/- DSS, MSBR alone, MSBR with dextran sulfate sodium (MSBR+DSS), and MSBR with DSS plus teduglutide (GLP-2 analogue)...Furthermore, genetic knockout of gcg, i.e. complete ablation of GLP-2 secretion capacity, diminishes resection-triggered barrier- and growth response, while DSS-colitis, i.e. incomplete ablation of GLP-2 secretion capacity, diminishes resection-triggered barrier-, but not growth response. Thus, GLP-2-deficiency with small intestinal barrier dysfunction may be an inflammation-independent mechanism ultimately contributing to malnutrition in severe colitis."

Preclinical • Crohn's disease • Inflammatory Bowel Disease • Ulcerative Colitis • CLDN2 • GCG

Successful Pregnancy in a Patient with Crohn's Disease and Short Bowel Syndrome: Off Total Parenteral Nutrition and On Teduglutide, a Glucagon-Like Peptide-2 Analog - A Case Report. (PubMed, Case Rep Gastroenterol) - "GLP-2 analogs helped with the nutritional management of patients with SBS during pregnancy and helped them wean off TPN. There is a need for further research and exploration into GLP-2 analogs as viable alternatives to conventional treatments such as TPN in the care and management of SBS patients during pregnancy."

Journal • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Short Bowel Syndrome

Forty-eight months outcomes of Teduglutide in adult stable patients with short bowel syndrome and home parental nutrition dependence: a real-world italian single center observational cohort study (ECCO-IBD 2025) - "No endoscopic neoplastic lesions were observed up to the 48th month of TED therapy. Conclusion This real-world experience allows us to state that, after 48 months of treatment, TED: a) is a safe therapy with minimal side effects: b) produces a rapid reduction in PS volumes in 40% of treated patients; c) consents to weaned off PS in 20% of enrolled patients; d) maintains a stable nutritional state and, finally, e) significantly improves Qol."

Clinical • Observational data • Real-world • Real-world evidence • Crohn's disease • Immunology • Inflammatory Bowel Disease

Glucagon-like peptides agonists promote maturation of intestinal organoids derived from neonates with necrotizing enterocolitis. (PubMed, Pediatr Surg Int) - "Patient-derived organoids provide a suitable ex vivo model to study NEC pathogenesis. Increasing GLP signaling in HIOs enhanced maturation of organoids derived from uninjured and injured neonatal human intestine. Further studies are underway to assess in vivo, the efficacy of GLP agonist administration in NEC. This study opens the way to future development of precision medicine in the treatment of NEC."

Journal • Gastrointestinal Disorder • Inflammation

Encapsulation of hydrophobically ion-paired teduglutide in nanoemulsions: Effect of anionic counterions. (PubMed, Food Chem) - "Additionally, rTGT/SDS_NE achieved the highest upregulation of genes associated with intestinal function (VIL1, SGLT1, and GLUT2), although the differences were not statistically significant. These findings highlight the potential of the hydrophobic ion-pairing of rTGT with SDS and its encapsulation in nanoemulsion for efficient delivery of rTGT, suggesting promise for advancing oral peptide therapeutics."

Journal • VIL1

Forty-eight months outcomes of teduglutide treatment in adult stable patients with short bowel syndrome and home parenteral nutrition dependence: A real-world Italian single-center observational cohort study. (PubMed, Nutrition) - "This real-world experience allows us to state that, after 48 months of treatment, TED: 1) is a safe therapy with minimal, rare side effects; 2) produces a rapid reduction in PS volumes in 40% of treated patients; 3) consents 20% of enrolled patients to be weaned off PS; 4) maintains a stable nutritional state and, finally, 5) significantly improves the QoL."

Journal • Observational data • Real-world • Real-world evidence • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Oncology • Short Bowel Syndrome

Successful Use of Glucagon-Like Peptide 1 Receptor Agonists for the Treatment of Short Gut Syndrome in Patients With Inflammatory Bowel Disease (AIBD 2024) - "The use of GLP-2 analogue, teduglutide, has been shown to be safe and effective therapy for treatment of short gut syndrome in patients with Crohn's disease; however, its use has been highly restrictive... Together these cases support the use of GLP-1 targeted therapies for the treatment of symptoms of short gut syndrome such as high bowel frequency and dehydration is effective and safe in IBD patients."

Clinical • Crohn's disease • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis

Therapeutic interventions targeting enteropathy in severe acute malnutrition modulate systemic and vascular inflammation and epithelial regeneration. (PubMed, EBioMedicine) - "Interventions aimed at ameliorating malnutrition enteropathy showed plausible effects on biomarkers of inflammation and epithelial regeneration, demonstrating an interdependence of systemic inflammation and enteropathy markers seen in structural analysis. Given the interplay between inflammation and tissue restoration in malnutrition, this mechanism of action supports larger trials to determine the clinical benefits of interventions, either alone or in combination, in children with complicated SAM."

Journal • Inflammation • Metabolic Disorders • CD14 • IGFBP3 • IL1R1 • VEGFA